Company Overview

Avivagen Inc. is a Canada-based life sciences and animal health company focused on developing and commercializing products intended to support livestock health and productivity without relying on antibiotics. The company operates primarily in the animal nutrition and feed additive industry, with a strategic emphasis on products designed to promote animal performance, immune function, and food production efficiency. Avivagen’s principal commercial platform is its proprietary oxidized beta-carotene technology marketed under the OxC-beta brand, which is incorporated into feed formulations for poultry, swine, and dairy cattle production.

The company’s primary revenue drivers are sales of OxC-beta feed additive products through commercial distribution partnerships and direct relationships in agricultural markets. Avivagen has historically focused on regions with large-scale livestock industries, including parts of Asia, North America, and Latin America. The company evolved from earlier biotechnology and nutraceutical activities into a more concentrated animal health and feed technology business, aligning its strategy with global efforts to reduce antibiotic use in food-producing animals while maintaining herd and flock productivity.

Business Operations

Avivagen’s operations are centered on the development, manufacturing coordination, regulatory approval, and commercialization of its OxC-beta Livestock product line. The company generates revenue primarily through feed additive sales and distribution agreements targeting commercial livestock producers and feed manufacturers. Its products are designed to function as non-antibiotic feed ingredients intended to improve immune response, animal health outcomes, and production efficiency. Avivagen has pursued regulatory clearances and product registrations across multiple jurisdictions to support broader market adoption.

The company maintains commercial activities in both domestic and international markets, with notable emphasis on livestock-intensive regions in Southeast Asia, Mexico, Brazil, and North America. Avivagen relies on a combination of internal scientific development capabilities and external manufacturing and distribution relationships. The company has also worked with regional distribution partners and agricultural industry participants to expand adoption of its feed additive technologies. Public disclosures indicate ongoing efforts to strengthen commercial penetration in poultry and swine sectors, where demand for antibiotic alternatives has increased due to evolving regulatory standards and consumer preferences.

Strategic Position & Investments

Avivagen’s strategic direction has focused on expanding commercial adoption of OxC-beta products while positioning the company within the broader transition toward antibiotic-reduction strategies in animal agriculture. Growth initiatives have included securing feed approvals in additional jurisdictions, increasing distributor relationships, and expanding use cases across multiple livestock species. The company has also emphasized scientific validation through animal performance studies and industry trials intended to support market acceptance among feed producers and integrators.

The company’s investments have primarily centered on intellectual property development, regulatory approvals, commercialization infrastructure, and market expansion rather than large-scale acquisitions. Avivagen’s proprietary oxidized carotenoid technology represents its principal strategic asset and differentiator within the feed additive sector. The company operates in a competitive landscape that includes animal nutrition firms, specialty feed additive manufacturers, and agricultural biotechnology companies focused on alternatives to antibiotic growth promoters and immune-support technologies.

Geographic Footprint

Avivagen is headquartered in Ottawa, Ontario, Canada, and operates through commercial networks that reach multiple international livestock markets. The company’s activities have been particularly concentrated in Asia-Pacific markets, where poultry and swine production volumes are significant and demand for feed efficiency technologies remains strong. Commercial presence has also extended into Latin America, especially Mexico and Brazil, as well as selected opportunities in North America.

The company’s international footprint is driven primarily through product registrations, distributor partnerships, and relationships with feed manufacturers and livestock producers rather than large-scale owned production infrastructure. Avivagen’s strategic market focus reflects regions where producers are increasingly seeking alternatives to traditional in-feed antibiotics due to regulatory changes, export requirements, and evolving food safety standards.

Leadership & Governance

Avivagen has been led by executives with backgrounds in biotechnology, animal nutrition, commercialization, and public company management. The company’s governance structure follows Canadian public company standards and includes oversight by a board of directors and executive leadership team focused on commercialization, regulatory strategy, and scientific development. Public filings and corporate disclosures indicate that leadership has prioritized disciplined capital management, regulatory expansion, and growth in international feed markets.

Key executives associated with Avivagen’s leadership include:

• Kym Anthony – Chief Executive Officer
• Kenneth MacLeod – Chief Financial Officer
• Dr. Graham Burton – Executive Chairman
• Dr. John O’Toole – Scientific and Technical Leadership Roles (historically associated with product development initiatives)

Certain executive roles and leadership assignments have changed over time in company disclosures. Data inconclusive based on available public sources regarding the most current status of some historical executive appointments.